Dendritic cell-based vaccination in solid cancer

Journal of Clinical Oncology

Volumn 21, Issue 1, 2003, Pages 135-142

  Stift, A ^a   Friedl, J ^a   Dubsky, P ^a   Bachleitner Hofmann, T ^a   Schueller, G ^a   Zontsich, T ^a   Benkoe, T ^a   Radelbauer, K ^a   Brostjan, C ^a   Jakesz, R ^a   Gnant, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2; TUMOR MARKER;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; DENDRITIC CELL; DIGESTIVE SYSTEM TUMOR; ENDOCRINE TUMOR; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DENDRITIC CELLS; DIGESTIVE SYSTEM NEOPLASMS; ENDOCRINE GLAND NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 18744411513     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.02.135     Document Type: Article

References (24)

1. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321, 1986
2. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987
3. Topalian SL, Solomon D, Avis FP, et al: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Clin Oncol 6:839-853, 1988
4. Steinman RM, Adams JC, Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. J Exp Med 141:804-820, 1975
5. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332, 1998
6. Holtl L, Rieser C, Papesh C, et al: CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet 352:1358, 1998 (letter)
7. Hsu FJ, Benike C, Fagnoni F, et al: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52- 58, 1996
8. Small EJ, Fratesi P, Reese DM, et al: Immunotherapy of hormonerefractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18:3894-3903, 2000
9. Shimizu K, Fields RC, Giedlin M, et al: Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci U S A 96:2268-2273, 1999
10. Correale P, Campoccia G, Tsang KY, et al: Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. Results from a phase Ib clinical trial. Eur J Cancer 37:892-902, 2001
11. Kern F, Surel IP, Brock C, et al: T-cell epitope mapping by flow cytometry. Nat Med 4:975-978, 1998
12. Pickl WF, Majdic O, Kohl P, et al: Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. J Immunol 157:3850-3859, 1996
13. Zhou LJ, Tedder TF: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 93:2588-2592, 1996
14. Brossart P, Stuhler G, Flad T, et al: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58:732-736, 1998
15. Shimizu K, Fields RC, Redman BG, et al: Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2. Cancer J Sci Am 6:S67-S75, 2000 (suppl 1)
16. Bonini C, Lee SP, Riddell SR, et al: Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol 166:5250-5257, 2001
17. Fujii S, Fujimoto K, Shimizu K, et al: Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: Induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients. Cancer Res 59:2150-2158, 1999
18. Chen B, Shi Y, Smith JD, et al: The role of tumor necrosis factor alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro. Blood 91:4652-4661, 1998
19. Dhodapkar MV, Steinman RM, Krasovsky J, et al: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233-238, 2001
20. Asavaroengchai W, Kotera Y, Mule JJ: Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A 99:931-936, 2002
21. Kundu SK, Engleman E, Benike C, et al: A pilot clinical trial of HIV antigen pulsed allogenic and autologous dendritic cell therapy in HIVinfected patients. AIDS Res Hum Retroviruses 14:551-560, 1998
22. Fong L, Brockstedt D, Benike C, et al: Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166:4254- 4259, 2001
23. Schott M, Seissler J, Lettmann M, et al: Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 6:4965-4969, 2001
24. Bachleitner-Hoffmann T, Stift A, Friedl J, et al: Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinomas using tumor lysate pulsed dendritic cells. J Clin Endocrinol Metab 3:1098- 1104, 2002